Alcohol Septal Ablation for Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy

Abstract

To provide a contemporary review of data regarding patient selection and outcomes for patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) undergoing septal reduction therapy with alcohol septal ablation (ASA). This review focuses on recent guideline updates from the USA and Europe, multiple recently published large multicenter, multinational registries of patients being treated with ASA, and a recent review of “real world” outcomes of ASA and surgical myectomy (SM) treated in hospitals in the USA. Recent data have demonstrated that ASA is a safe procedure and is effective for the reduction of symptoms associated with obstructive HCM. Both short-and long-term outcomes after ASA appear similar to outcomes in patients undergoing SM and medical treatment. Outcomes in a real-world setting evaluating ASA and SM outside of high volume centers specializing in treatment of HCM show that ASA is increasing in use and that outcomes are fairly consistent across centers performing the procedure.